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Abstract Status of tumor progression (either remaining in situ,
or becoming invasive/metastatic) may be de¢ned largely by
subtle interactions (‘cross-talk’) in a microenvironment formed
by interfacing tumor cell and host cell membrane domains
(termed ‘glycosynapses’) involved in glycosylation-dependent
cell adhesion and signaling. Functional roles of tumor-associated
gangliosides, organized in glycosynapses of three types of tumor
cell lines, are discussed. Gangliosides function as adhesion re-
ceptors or as ‘sensors’ that can be stimulated by antibodies, with
consequent activation of signal transducers leading to enhanced
motility and invasiveness.
& 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Invasive/metastatic properties of tumor cells are controlled
by multiple factors with complex machinery, many of which
operate at the surface membrane. Of particular importance is
the high expression of aberrant glycosphingolipids (GSLs) in
speci¢c types of tumors, which are involved in tumor cell
adhesion and signal transduction, and thus de¢ne stage of
tumor progression and invasiveness [1,46]. Recent studies in-
dicate that GSLs and transmembrane glycoproteins, including
adhesion receptors and growth factor receptors, as well as
cytoplasmic signal transducers (TDs), are not randomly dis-
tributed, but rather assembled non-covalently in multiple
types of microdomains (e.g. for review [2^5]).
Some of these microdomains de¢ne glycosylation-depen-
dent adhesion and signaling and are termed ‘glycosynapses’
[6] ; they may provide a microenvironment where tumor cells
interface with host cells [7]. Such interfacing membrane units
may de¢ne the ‘destiny’ of tumor cells, e.g. whether to di¡er-
entiate or to follow an apoptotic pathway; whether to prolif-
erate or to modify original malignancy; whether to activate
motility and proteolysis to invade through extracellular matrix
into microvasculature, leading to distant metastasis [1,46].
In this review, we propose a conceptual scheme for cross-
talk of tumor cells with host cells through their interfacing
glycosynapses, to de¢ne destiny of tumor cells.
2. Self-assembly of GSLs in membrane: cis vs. trans interaction
GSLs in membrane (i) interact side-by-side within the same
membrane to form clusters (cis interaction), or (ii) interact
through their carbohydrate surfaces between two interfacing
membranes (trans interaction). Many electron microscopy
studies using labeled anti-GSL antibodies have revealed re-
markable GSL clusters at the cell surface [8,9], or on liposome
surface even in the absence of cholesterol [10]. GSLs are
presumed to have greater ability to both donate and accept
hydrogen bond through the hydroxyl group of sphingosine,
acylamide group, or glycosyl residue, compared to glycero-
phospholipids that have only the ability to accept hydrogen
bond (this possibility cannot yet be con¢rmed, since solid-
phase nuclear magnetic resonance is not practically devel-
oped). Sphingomyelin may interact with cholesterol whereas
it separates from glycerophospholipids in gel state, as indi-
cated by spin-label ESR and IR spectroscopy [11,12].
On the other hand, trans interaction between GSLs pro-
vides the basis for GSL-dependent cell-to-cell adhesion; it
takes place through speci¢c complementary structures and is
catalyzed in many cases by Ca2þ. There are steadily increasing
examples of such complementary GSL pairs providing a basis
for cell-to-cell interaction [13,14], even though the concept
was greeted by considerable skepticism when it was initially
proposed [15^17]. Recently, such carbohydrate-to-carbohy-
drate interactions have been elucidated on a quantitative ba-
sis, using surface plasmon resonance (SPR) spectroscopy [18^
20], aggregation of gold glyconanoparticles [21], molecular
force microscopy [22,23], and pressure-area (Z-A) isotherms
in GSL Langmuir monolayer [24].
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Self-clustered GSLs in glycosynapse are often associated
with TD proteins having long aliphatic chain (e.g. cSrc, Src
family kinases, Ras, RhoA), or with other TDs (e.g. FAK,
paxillin) [25]. Thus, GSL-clustered domains, previously
termed ‘GEM’ (glycolipid-enriched microdomain) or ‘GSD’,
are involved in GSL-dependent cell adhesion that induces
activation of such TDs to initiate signals to modify cellular
phenotype. Such domains are separable from caveolae by im-
munoprecipitation or immunoadsorption with antibodies to
GSLs or caveolin, and are distinguishable by chemical com-
position [26], or by application of photoactivatable ganglio-
side that does not bind to caveolin [27]. Glycosynapses of B16
melanoma cells are highly enriched in GM3, cSrc, RhoA, and
FAK, but have low level of cholesterol, and no caveolin. In
contrast, caveolar membrane is highly enriched in cholesterol,
caveolin, GlcCer, and Ras [26]. Caveolar membranes are not
involved in GSL-dependent adhesion or GSL-induced signal-
ing to modify cellular phenotype. Recently, we observed the
presence in GEM or GSD of lipophilic tetraspanin proteo-
lipids (PLs) such as CD9 [28] and MAL-like PLs (Handa,
K. et al., unpublished data), which may stabilize GSL micro-
domains and modulate signal transduction.
3. GM3-dependent adhesion and signaling in melanoma B16
cell glycosynapse
Metastatic and invasive abilities of mouse melanoma B16
cell variants, in the order BL6sF10sF1EWA4, are closely
correlated with level of GM3 surface expression [29], and also
with degree of adhesion to cultured endothelial cells (ECs)
(mouse SPE1; human umbilical vein ECs) in vitro [29,30].
Such adhesion is not selectin- or integrin/ICAM1-dependent;
the process is presumed to be based on interaction of GM3
with LacCer (expressed highly on SPE1 or human umbilical
vein ECs), or with Gg3Cer (assumed to be expressed on
mouse lung ECs) [30]. BL6 or F10 cells bound strongly to
Gg3Cer-coated plates, whereas F1 or WA4 did not [17].
This process was therefore termed ‘GM3-dependent cell adhe-
sion’. Haptotactic or phagokinetic motility of BL6 or F10
cells was strongly promoted on Gg3Cer-coated surface
[17,30]. This mechanism is synergistic with integrin-dependent
adhesion and motility, as demonstrated on plates co-coated
with GSL (Gg3Cer or LacCer) and extracellular matrix pro-
tein (¢bronectin or laminin) [31].
The signaling process at the interface between melanoma
and EC glycosynapses is therefore of crucial importance in
melanoma progression and metastasis. We have been able to
examine signaling and phenotypic changes in melanoma cells,
but not yet in ECs. Results indicated that GM3-dependent
B16 cell adhesion induces tyrosine phosphorylation of cSrc
and FAK, as well as enhancing GTP binding to RhoA and
Ras [25,26]. The downstream signaling pathway in this case is
not yet clear, but activation of MAPK has been observed, and
is modulated by presence of PLs. RhoA activation may well
induce motility enhancement, but this remains to be studied.
What are the signaling and phenotypic changes that occur in
ECs interfacing with B16 cells? It seems plausible that ECs are
activated to express ICAM receptor that interacts with mela-
noma cell integrin [32], or alternatively retract to create larger
intercellular spaces (e.g. [33]) through which the melanoma
cells can pass.
4. Disialyl-GalNAc-Lc4Cer (RM2 antigen) that promotes
metastasis of renal cell carcinoma
Metastatic properties of renal cell carcinoma (RCC) are
closely associated with presence of slow-migrating ganglio-
sides [34^36]. Two classes of gangliosides, one with globo-se-
ries, the other with type 1 lacto-series core, have been identi-
¢ed (see structures below; each de¢ned by mAb as indicated
in parentheses) [37^40].
Globo-series gangliosides: MSGb5 (RM1) [37] NeuAcK3-
GalL3GalNAcL3GalK4GalL4GlcLCer; DSGb5 (5F3) [38]
NeuAcK3GalL3[NeuAcK6]GalNAcL3GalK4GalL4GlcLCer.
Type 1 lacto-series gangliosides: DSLc4 (FH9) [39] Neu-
AcK3GalL3[NeuAcK6]GlcNAcL3GalL4GlcLCer; DSGalNAcLc4
(RM2) [40] GalNAcL4[NeuAcK3]GalL3[NeuAcK6]GlcNAcL3-
GalL4GlcLCer.
All these gangliosides, cSrc, FAK, and RhoA are compo-
nents of glycosynapse. RM2 antigen was shown to be associ-
ated with these TDs when GEM fraction was treated with
RM2 antibody coupled to ‘HiTrap’ column. By electron mi-
croscopy using colloidal gold-coated RM2, large clusters of
antigens can be seen at the surface of RCC line TOS1 cells
[41].
The above three disialogangliosides in RCC were identi¢ed
as being bound to siglec7, which is expressed in peripheral
blood mononuclear cells (PBMC). TOS1 cell suspension,
when incubated with blood cells, forms large clumps with
PBMC. Binding of TOS1 cells to lung tissue sections [36] is
presumably due to presence of resident PBMC, and other
types of cells expressing siglec7 or other siglecs, in lung tissue.
A plausible (though still hypothetical) scenario is that (i) RCC
cells migrate into blood vessels and interact with siglec7-ex-
pressing hematopoietic cells; (ii) this results in large clumps of
tumor cells with PBMC; (iii) these aggregates lead to micro-
embolisms in microvasculature which is highly developed in
lung, with consequent lung metastasis [42].
5. Monosialyl-Gb5 (MSGb5) in glycosynapse of MCF-7 cells :
cell migration and invasiveness are induced through signaling
from monosialyl-Gb5
A typical example of control of tumor cell invasiveness and
motility by ganglioside was demonstrated recently in human
mammary carcinoma MCF-7 variants 7/AZ and 7/6 [43]. Both
variants are non-invasive into collagen gel layer. Treatment of
7/AZ cells with anti-MSGb5 mAb RM1 greatly increased
their invasiveness into collagen gel layer and motility in
wound migration assay, whereas the same RM1 treatment
had no such e¡ect on 7/6. This RM1 e¡ect on 7/AZ was
highly speci¢c, i.e. mAbs directed to GM2, Gb3, or Gb5
had no e¡ect. All GSLs in 7/AZ and 7/6 were found in low-
density membrane fraction (GEM). Levels of TDs cSrc and
FAK; adhesion receptor integrins K1, K2, K3, E-cadherin, and
L-catenin; and O-linked mucins MUC1 and MUC4, were all
similar between the two variants.
The only clear di¡erence was found in level of CD9, which
was approximately four times higher in 7/AZ than in 7/6 cells.
CD9 was enriched in GEM fraction of 7/AZ, but virtually
absent in GEM of 7/6. A crucial distinction was that RM1
induced tyrosine phosphorylation of cSrc and FAK in 7/AZ,
but not 7/6, although chemical levels of cSrc and FAK were
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Fig. 1. Tumor progression through glycosylation-dependent cross-talk between glycosynapses interfacing tumor cells with host cells. A: Stages
of tumor cell interaction (T1^T3) in I, and subsequent tumor cell adhesion to ECs in microvessels (T4^T6) in II. Each stage is explained in the
text. Interfacing glycosynapses are indicated by yellow ovals, and integrins/growth factor receptors by black ovals. B: Three examples of inter-
facing glycosynapses. I: GSL to GSL. II: GSL to lectin. III: O-linked glycan to selectin or siglec. TDs and PLs are organized in glycosynapses
(pale yellow rounded rectangle). Stimulation by binding of GSLs or O-glycans activates TDs to send signals as indicated. PLs may modulate
signaling. Glycosynapse GSLs may be connected to TDs by interaction of longer fatty acyl residue (C22^24) of GSL with acyl chain of fatty
acid or farnesyl group of TD. An alternative connection of GSLs to TDs could be mediated by interaction of PLs through their hydrophobic
region with aliphatic chains of GSLs and TD, or interaction of GSL ceramide with hydrophobic domain of TD. Ligand binding to GSL or
O-linked glycan may induce clustering of such groups in glycosynapse, which activates TDs. C: Growth factor receptors (GFR) and integrins
(shown as black ovals in A) in glycosynapses which are not present in interfacing area. GFRs, integrins, and associated tetraspanins (TSP) are
highly glycosylated, and surrounded by gangliosides (Gg). Their functions are controlled by glycosylation in each microdomain. For further de-
tails, see [6].
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identical. MSGb5 in glycosynapse of 7/AZ cells may be con-
nected to cSrc or FAK through abundant presence of CD9,
whereas MSGb5 in glycosynapse of 7/6 cells has no such
connection, since CD9 is virtually absent in 7/6 glycosynapse.
Thus, a crucial di¡erence in organization of MSGb5 with cSrc
and FAK in glycosynapse is suggested [44].
6. Proposed scheme for microenvironment of tumor cells
interfacing with host cells, focused on glycosynaptic structure
Based on the data described in Sections 3^5, we hereby
propose a scheme for functional roles of interfacing glycosy-
napses of tumor cells with host cells during tumor progression
(see Fig. 1A, B).
The majority of human cancers are derived from epithelial
cells (EpCs). When transformed (tumor) cells arise, their ini-
tial contact is with the ‘parental’ EpCs and surrounding ¢bro-
blasts (F), as well as extracellular matrix (ECM) components,
particularly assembled in basement membrane (BM). In such
microenvironment, interfacing glycosynapses of tumor cells
with their host cells do not stimulate tumor cells, presumably
because GSLs in the interfacing glycosynapses may not be
aberrant in terms of quantity or quality (structure) (Fig.
1A,I, stage T1, i.e. in situ tumor cell). We presume that
when GSL pattern becomes aberrant, interfacing glycosynap-
ses are stimulated to induce signaling to activate tumor cell
motility and proteolysis, and break down BM and ECM
(stage T2). In this stage, integrin receptors complexed with
tetraspanin and gangliosides [28], as well as matrix metallo-
proteases [45], probably associated within the same glycosy-
napse, play an essential role in tumor cell migration and pen-
etration through BM and ECs. Interfacing of tumor cells with
ECs through their glycosynapses may activate tumor cell mo-
tility as well as EC retraction and expression of selectin and/or
ICAM, thereby facilitating tumor cell penetration into micro-
vasculature (stage T3). When tumor cells penetrate into blood
or lymphatic vessels, they migrate to a distant site to initiate
metastasis (Fig. 1A,II). If tumor cells express high level of
disialoganglioside in glycosynapse, they bind to blood cell
siglec, leading to formation of tumor cell^blood cell aggre-
gates and consequent microembolisms (stage T4). Some tumor
cells highly expressing sialyl-Lex, sialyl-Lea, or their analogues
are capable of binding to E-selectin (stage T5). Adhesion of
tumor cells to ECs may take place through their interfacing
glycosynapses, leading to activation of both tumor cells and
ECs. Tumor cells are thereby translocated out of vessels to
initiate metastatic deposits, and interface with parenchyma-
tous cells (P) or ¢broblasts (F) to stimulate tumor cell growth
and motility (stage T6).
Examples of composition and possible organization of gly-
cosynapse pairs interfacing tumor cells to host cells are de-
picted in Fig. 1B and its legend. In each case, glycosylation-
mediated cross-talk takes place through mutual interaction of
GSLs or O-linked glycans on interfacing glycosynapses. The
exact mechanism by which GSLs are connected to TDs is
unclear. One possibility is acyl chain interaction by the pres-
ence of longer fatty acids in GSLs; another is connection
through PLs (see Fig. 1B, legend). In addition to glycosyla-
tion-mediated interaction between interfacing glycosynapses,
tumor cell proliferation and motility are strongly controlled
Fig. 1 (Continued).
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by presence of growth factor receptors (GFR), and integrins
complexed with tetraspanins (TSP) and gangliosides (Gg),
which in many cases are included within glycosynapse or sim-
ilar domain, but may not be interfacing (Fig. 1C).
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